Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-05
DOI
10.1038/s41598-021-89013-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- A Mouse Model of SARS-CoV-2 Infection and Pathogenesis
- (2020) Shi-Hui Sun et al. Cell Host & Microbe
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neurologic Features in Severe SARS-CoV-2 Infection
- (2020) Julie Helms et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of a DNA vaccine candidate for COVID-19
- (2020) Trevor R. F. Smith et al. Nature Communications
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- (2020) Jia Liu et al. Cell Discovery
- A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
- (2020) Ahmed O. Hassan et al. CELL
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
- (2020) Pauline Maisonnasse et al. NATURE
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
- (2020) Kizzmekia S. Corbett et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
- (2020) David R. Boulware et al. NEW ENGLAND JOURNAL OF MEDICINE
- 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice
- (2020) Athri D. Rathnayake et al. Science Translational Medicine
- A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19
- (2020) Seyed MohammadReza Hashemian et al. Drug Design Development and Therapy
- Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
- (2020) Andrea J. Pruijssers et al. Cell Reports
- Current Perspective of Antiviral Strategies against COVID-19
- (2020) Bintou A. Ahidjo et al. ACS Infectious Diseases
- Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia
- (2020) David H. Brann et al. Science Advances
- Central Nervous System Targets and Routes for SARS-CoV-2: Current Views and New Hypotheses
- (2020) Francisco J. Barrantes ACS Chemical Neuroscience
- Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
- (2020) Stuart Weston et al. JOURNAL OF VIROLOGY
- Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
- (2020) Suzanne J. F. Kaptein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
- (2020) Lifeng Fu et al. Nature Communications
- Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
- (2020) Wayne Vuong et al. Nature Communications
- Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease
- (2020) Joseph W. Golden et al. JCI Insight
- Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection
- (2020) Sang Heui Seo et al. Vaccines
- Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
- (2020) Qingxin Li et al. Microorganisms
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
- (2020) Fatai S. Oladunni et al. Nature Communications
- Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
- (2017) Niels C Pedersen et al. JOURNAL OF FELINE MEDICINE AND SURGERY
- Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor
- (2016) Yunjeong Kim et al. PLoS Pathogens
- Broad-Spectrum Inhibitors against 3C-Like Proteases of Feline Coronaviruses and Feline Caliciviruses
- (2015) Yunjeong Kim et al. JOURNAL OF VIROLOGY
- Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses
- (2012) Y. Kim et al. JOURNAL OF VIROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started